In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Actinium Pharmaceuticals (NYSE: ATNM), with a price target of $3. The company’s shares opened today at $0.60.
McCarthy commented:
“Hematology (ASH, 12/1-12/4) meeting were released this morning and for Actinium this year is particularly key in our view as we will see the early data from the P3 SIERRA trial for Iomab in end- stage acute myeloid leukemia (AML). The data will be an oral presentation and from the abstract release the data thus far are impressive.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 3.8% and a 39.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Actinium Pharmaceuticals with a $4 average price target, which is a 562.1% upside from current levels. In a report issued on October 29, Oppenheimer also assigned a Buy rating to the stock.
.
See today’s analyst top recommended stocks >>
Based on Actinium Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $4.86 million. In comparison, last year the company had a GAAP net loss of $6.32 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Actinium Pharmaceuticals, Inc. engages in the development of targeted therapies for patients with cancers lacking effective treatment options. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells.
